TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2371435
Drug: 12 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 micrograms inhaled formoterol
Study: 2371435
Drug: 24 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 micrograms inhaled formoterol
Study: 349841
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of nitrous oxide in the lower extremities as part of conservative treatment.
Study: 349841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitrous oxide injection).
Study: 31699572
Drug: Bihemispheric tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Study: 31699572
Drug: Sham bihemispheric
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Study: 29608733
Drug: Physical therapist-administered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapist-administered physical activity intervention including a wearable activity tracking device, individualized step goals, and face-to-face feedback
Study: 29608733
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy alone after TKR
Study: 24058189
Drug: Acetaminophen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (oral dose)
Study: 23707270
Drug: Tanezumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (5 or 10mg intravenous, up to 2 doses in 8-week intervals)
Study: 23707270
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 to 40 mg every 12 hours)
Study: 18657146
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 mug ethinyl estradiol and 150 mug levonorgestrel) administered daily for 21 days starting on the first day of the menstrual cycle.
Study: 18657146
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC) in the first week of the cycle.
Study: 3513357
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) at a dose of 30 ng/kg . min
Study: 29287664
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) in combination with Contingency Management (CM)
Study: 29287664
Drug: ACT+CM in
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT+CM in combination with modafinil
Study: 22369682
Drug: High-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose proton pump inhibitors (80 mg bolus, followed by pantoprazole 8 mg/h infusion, n = 100)
Study: 22369682
Drug: Standard-dose proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose proton pump inhibitors (pantoprazole 40 mg bolus daily, n = 101)
Study: 12576970
Drug: Mannitol administration
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol administration for >72 hrs (group 1)
Study: 12576970
Drug: Mannitol administration
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol administration for 24 to 48 hrs (group 2)
Study: 2002646
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A therapy (10 mg/kg/day)
Study: 2002646
Drug: Blood transfusions
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusions (3 to 5 third-party transfusions at two weekly intervals)
Study: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (G/P) 8-week treatment
Study: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (G/P) 12-week treatment
Study: 30421537
Drug: Glecaprevir/Pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/Pibrentasvir (G/P) 16-week treatment
Study: 22669067
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) including hypnosis; 6-session program
Study: 22669067
Drug: Conservative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative standard treatment for TMD
Study: 15966131
Drug: Combination inhaled
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaled corticosteroids and long acting beta agonists (ICS/LABA)
Study: 10561258
Drug: Chemoradiation (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (epirubicin 60 mg/m(2)) followed by adjuvant chemotherapy (epirubicin 90 mg/m(2) at 4-week intervals for five cycles)
Study: 8607100
Drug: Ethyl icosapentatenoate
Normalized name: Ethyl Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks
Study: 1309115
Drug: hMG (FSH:LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG (FSH:LH = 1:1) administered to 18 patients (group A)
Study: 1309115
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified hMG (FSH:LH = 19:1) administered to 19 patients (group B)
Study: 3918356
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sodium cromoglycate aerosol
Study: 3918356
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sodium cromoglycate aerosol
Study: 3918356
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium cromoglycate aerosol
Study: 3918356
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg nebulised sodium cromoglycate
Study: 30516064
Drug: 2016 American
Normalized name: American Ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2016 American College of Sports Medicine guidelines (aerobic)
Study: 30516064
Drug: 2016 American
Normalized name: American Ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2016 American College of Sports Medicine guidelines (flexibility and resistance)
Study: 26620682
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anaesthesia
Study: 22789440
Drug: Ceftriaxone (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1g intravenously in a single dose before surgery)
Study: 22789440
Drug: Cefazolin (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1g intravenously in a single dose before surgery)
Study: 20508026
Drug: AS03(B) adjuvanted
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(B) adjuvanted split virion vaccine
Study: 20508026
Drug: Non-adjuvanted whole
Normalized name: HYACINTHOIDES NON-SCRIPTA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted whole virion vaccine
Study: 18593681
Drug: Insulin administered
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin administered via pen devices (n = 49)
Study: 15973830
Drug: Ultrasonic periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic periodontal treatment (Group 1)
Study: 15973830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 3) - adults without PD, Community Periodontal Index of Treatment Needs = 0
Study: 12048127
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 5 mg/day
Study: 12048127
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 5 mg/day plus vitamin C 500 mg/day
Study: 10453490
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (GH) 0.15 IU/(kg.day)
Study: 10453490
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (GH)
Study: 2455109
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg b.i.d. in a slow-release formulation)
Study: 2455109
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and Atenolol combination
Study: 29476776
Drug: Propranolol (nonspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (nonspecific β1‐, β2‐adrenergic receptor inverse agonist)
Study: 27720505
Drug: S-AM/TEL 2.5/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-AM/TEL 2.5/40 mg
Study: 27720505
Drug: S-AM/TEL 5/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-AM/TEL 5/40 mg
Study: 27720505
Drug: TEL 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEL 80 mg
Study: 20820459
Drug: Zoom 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zoom 2 bleaching agent applied to labial surfaces
Study: 20820459
Drug: No bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bleaching treatment (Control)
Study: 20820459
Drug: Polishing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polishing treatment for both groups
Study: 18005078
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise (twice weekly for 12 weeks)
Study: 18005078
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal treatment including encouragement to walk regularly)
Study: 16633088
Drug: Indapamide (IND)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (IND) 2.5 mg od
Study: 16633088
Drug: Bendroflumethiazide (BDZ)
Normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bendroflumethiazide (BDZ) 2.5 mg od
Study: 14633756
Drug: Sufentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil TCI (0.25 ng x ml(‐1) effect‐site concentration at extubation)
Study: 14633756
Drug: Remifentanil TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI with morphine bolus (0.15 mg x kg(‐1))
Study: 8827850
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg estradiol added to neuroleptic treatment for eight weeks
Study: 8827850
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment alone
Study: 7967338
Drug: Aspirin, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 320 mg/day
Study: 30222637
Drug: Subcutaneous microneedle
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous microneedle RF treatment (67°C/4‐second duration)
Study: 27977720
Drug: RBANS neurocognitive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RBANS neurocognitive test battery administered on admission and again at discharge (mean time 4.1 weeks, SD 1.86 weeks)
Study: 25509967
Drug: Rajyoga meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rajyoga meditation in addition to routine medical treatment (analgesics and muscle relaxants)
Study: 25509967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (analgesics and muscle relaxants only)
Study: 17706461
Drug: Multiplayer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplayer group (participated in a weekly IDSVG multiplayer class)
Study: 10361649
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training plus relaxation therapy (relaxation group; n = 76)
Study: 7741790
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide‐HCl (Cerucal)
Study: 155507
Drug: Halcinonide-neomycin-amphotericin (HNA)
Normalized name: halcinonide / neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halcinonide-neomycin-amphotericin (HNA) cream
Study: 29136453
Drug: Locoregional interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional interferon beta (3 million units once per day for 10 consecutive days every 8 weeks for a total of 3 courses, then 1-day injection every 4 weeks for 2.5 years)
Study: 1511646
Drug: Loperamide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (10 mg)
Study: 1511646
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide (10 mg)
Study: 23308361
Drug: Nutraceuticals containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceuticals containing soy isoflavones (60 mg) and berberine (500 mg)
Study: 21127274
Drug: Aortic valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic valve replacement (AVR) with warfarin treatment
Study: 19149269
Drug: Sodium ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferulate intravenous drip after 24 hours
Study: 19149269
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (dehydrating, cytidine diphosphocholine, controlling blood pressure, blood sugar and complicating diseases)
Study: 12680747
Drug: Sertraline (adequate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (adequate treatment)
Study: 12680747
Drug: Placebo (adequate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (adequate treatment)
Study: 10890988
Drug: Corticosteroids alone
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids alone (methylprednisolone or prednisolone at 1 mg/kg, increased by 50% every 5 to 10 days)
Study: 10890988
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus cyclosporine (5 mg/kg)
Study: 8822971
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg SDZ‐WAG 994
Study: 8822971
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg SDZ‐WAG 994
Study: 8822971
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SDZ‐WAG 994
Study: 3913459
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (200 mg 4 times daily) for up to 12 weeks
Study: 3913459
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir and Placebo
Study: 3913459
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Oral acyclovir
Study: 28549799
Drug: Pharmacist-led patient-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led patient-centered pharmaceutical care (PC)
Study: 23676632
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) acupuncture (AP)
Study: 23676632
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (verum CHM)
Study: 20152665
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) during orthodontic treatment in group 1 (25 patients)
Study: 18836152
Drug: Diagnosed diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosed diabetes (self-reported diabetes or diabetic medication use; n = 163)
Study: 18836152
Drug: Undiagnosed diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed diabetes; n = 55)
Study: 18836152
Drug: Impaired fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744)
Study: 8632540
Drug: Preoperative M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative M-VAC chemotherapy (2 courses before surgery and 3 courses after surgery)
Study: 8632540
Drug: Postoperative M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative M-VAC chemotherapy (5 adjuvant courses following cystectomy)
Study: 8632540
Drug: Preoperative M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative M-VAC chemotherapy
Study: 8632540
Drug: Postoperative M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative M-VAC chemotherapy
Study: 26946729
Drug: menstrual cycle-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: menstrual cycle-based acupuncture therapy
Study: 22293584
Drug: Statin +
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin + EPA (1,800 mg/day for 6 months)
Study: 12401596
Drug: Caudal bupivacaine/neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine/neostigmine mixture (0.25% bupivacaine 1 mL/kg + neostigmine 2 micro g/kg)
Study: 12401596
Drug: Caudal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal bupivacaine (0.25% bupivacaine 1 mL/kg)
Study: 12401596
Drug: Caudal neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal neostigmine (2 micro g/kg in normal saline 1 mL/kg)
Study: 8560532
Drug: Amodiaquine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (35 mg/kg over 3 days)
Study: 2128475
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) 6 mg/day
Study: 2128475
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GST) 50 mg/week
Study: 2128475
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GST) 50 mg/month after dose reduction
Study: 2128475
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) 4 mg/day after dose reduction
Study: 28345162
Drug: Lixisenatide (10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10 µg initially increased weekly by 5 up to 20 µg)
Study: 28345162
Drug: Sitagliptin (50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg once daily)
Study: 26087566
Drug: Sophora gel
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sophora gel (one piece every night for 14 days) and Fluconazole capsules (150 mg, once every three days, four times in total)
Study: 26087566
Drug: Fluconazole capsules
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsules (control group)
Study: 26087566
Drug: Sophora gel
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sophora gel combined with Fluconazole capsules
Study: 22837542
Drug: Early enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early enhanced speech and language therapy after stroke
Study: 21860188
Drug: Amiodarone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (3 mg/kg in 100 ml normal saline)
Study: 17485450
Drug: Morphine, atropine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine, atropine, and suxamethonium
Study: 9593137
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO
Study: 9593137
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of OFLO plus 100 mg of MINO
Study: 7923315
Drug: Clebopride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (0.5 mg) and simethicone (200 mg)
Study: 3380312
Drug: Dantrolene sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene sodium (25 mg, twice a day for seven days)
Study: 21697532
Drug: MVA85A with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA85A with EPI vaccines
Study: 21697532
Drug: EPI vaccines
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI vaccines alone
Study: 19383885
Drug: High triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High triglycerides (> or =136 mg/dL)
Study: 11348910
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release oral morphine
Study: 8489572
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fluconazole suppository
Study: 8489572
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg fluconazole suppository
Study: 8489572
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg and 25 mg fluconazole suppositories
Study: 28961427
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg) and codeine phosphate (30 mg)
Study: 28961427
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (50 mg)